Trial
NCT03208244
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
—
Condition
End Stage Heart Disease
Intervention
Clinically prescribed direct acting antiviral
Why stopped
Protocol transitioned to standard of care, no funding available to support research work
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-22